Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 21
Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedFeb 21, 2025
DataAggregated Company Financials
Companies565
- 7D2.3%
- 3M-0.3%
- 1Y-1.4%
- YTD4.4%
In the last week, the Biotech industry is up 2.3%, with AbbVie up 3.8%. Meanwhile, Alnylam Pharmaceuticals actually underperformed within the industry, shrinking 5.2% in the last week. The industry has been flat over the past 12 months despite the gain this week. As for the next few years, earnings are expected to grow by 29% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 21 Feb 2025 | US$857.3b | US$117.0b | -US$37,500,625,878.71 | 16.9x | -22.9x | 7.3x |
| Sun, 19 Jan 2025 | US$947.4b | US$149.4b | -US$26,286,185,460.05 | 17.3x | -36x | 6.3x |
| Tue, 17 Dec 2024 | US$991.6b | US$150.0b | -US$26,487,519,670.88 | 16.7x | -37.4x | 6.6x |
| Thu, 14 Nov 2024 | US$1.1t | US$150.0b | -US$27,361,732,021.47 | 15x | -39x | 7.1x |
| Sat, 12 Oct 2024 | US$884.5b | US$113.1b | -US$36,028,289,614.54 | 20.6x | -24.6x | 7.8x |
| Mon, 09 Sep 2024 | US$874.9b | US$113.1b | -US$35,665,603,175.32 | 22.2x | -24.5x | 7.7x |
| Wed, 07 Aug 2024 | US$1.2t | US$165.8b | -US$32,869,773,768.90 | 23.9x | -35.3x | 7x |
| Fri, 05 Jul 2024 | US$1.1t | US$164.5b | -US$28,070,736,754.86 | 27.9x | -39.9x | 6.8x |
| Sun, 02 Jun 2024 | US$1.1t | US$164.6b | -US$26,677,143,877.65 | 27.4x | -42.1x | 6.8x |
| Tue, 30 Apr 2024 | US$1.1t | US$164.6b | -US$27,374,440,770.81 | 22.8x | -39.1x | 6.5x |
| Thu, 28 Mar 2024 | US$1.2t | US$164.4b | -US$23,823,048,661.67 | 21.5x | -49.4x | 7.2x |
| Sat, 24 Feb 2024 | US$1.2t | US$166.7b | -US$21,620,417,137.21 | 10.8x | -54.5x | 7.1x |
| Mon, 22 Jan 2024 | US$1.4t | US$204.8b | -US$22,505,807,764.00 | 18.5x | -63.4x | 7x |
| Wed, 20 Dec 2023 | US$1.4t | US$204.8b | -US$22,154,151,632.00 | 19.6x | -61.2x | 6.6x |
| Fri, 17 Nov 2023 | US$1.2t | US$204.7b | -US$22,125,754,712.00 | 16.5x | -54.7x | 5.9x |
| Sun, 15 Oct 2023 | US$1.3t | US$207.3b | -US$13,137,172,262.00 | 16.6x | -96.4x | 6.1x |
| Tue, 12 Sep 2023 | US$1.3t | US$207.6b | -US$12,635,687,518.00 | 17.5x | -101.7x | 6.2x |
| Thu, 10 Aug 2023 | US$1.3t | US$207.7b | -US$12,585,104,613.00 | 16.7x | -101.4x | 6.1x |
| Sat, 08 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Mon, 05 Jun 2023 | US$1.1t | US$185.9b | -US$16,012,816,022.00 | 11.4x | -71.1x | 6.1x |
| Wed, 03 May 2023 | US$1.2t | US$197.5b | -US$6,736,968,452.00 | 14.4x | -171.8x | 5.9x |
| Fri, 31 Mar 2023 | US$1.1t | US$198.6b | -US$3,738,200,739.00 | 13.9x | -303.7x | 5.7x |
| Sun, 26 Feb 2023 | US$1.1t | US$200.5b | -US$3,797,679,065.00 | 14.2x | -295.4x | 5.6x |
| Tue, 24 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.7x | 665x | 5.7x |
| Thu, 22 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.6x | 711.6x | 5.7x |
| Sat, 19 Nov 2022 | US$1.1t | US$202.2b | US$1.2b | 14.7x | 916.1x | 5.6x |
| Mon, 17 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Wed, 14 Sep 2022 | US$1.1t | US$206.9b | US$5.9b | 15.8x | 185.7x | 5.3x |
| Fri, 12 Aug 2022 | US$1.1t | US$207.0b | US$7.7b | 15.9x | 143.3x | 5.3x |
| Sun, 10 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Tue, 07 Jun 2022 | US$990.4b | US$212.7b | US$11.3b | 16x | 87.8x | 4.7x |
| Thu, 05 May 2022 | US$1.0t | US$201.2b | US$7.4b | 17.7x | 140.4x | 5.2x |
| Sat, 02 Apr 2022 | US$1.3t | US$227.1b | US$14.3b | 19.1x | 90.8x | 5.7x |
| Mon, 28 Feb 2022 | US$1.2t | US$222.9b | US$10.9b | 19.5x | 113.3x | 5.5x |
Price to Earnings Ratio
113.3x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 19% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.41% | |
| Healthcare | 0.18% | |
| Biotech | 2.30% | |
| Biotech | 2.30% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$200.88 | 3.8% +US$12.8b | 13.7% | PE83.7x | |
| GILD Gilead Sciences | US$110.03 | 3.8% +US$5.1b | 51.2% | PE285.7x | |
| VRTX Vertex Pharmaceuticals | US$480.33 | 3.8% +US$4.6b | 12.5% | PS11.2x | |
| REGN Regeneron Pharmaceuticals | US$696.02 | 3.2% +US$2.3b | -27.9% | PE16.9x | |
| ONC BeiGene | US$244.20 | 8.3% +US$2.0b | 58.8% | PS8x |
